Study of Arginine Free IED in Critically Ill Patients. (ROSIED)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Thai Otsuka Pharmaceutical Co.,Ltd.
ClinicalTrials.gov Identifier:
NCT01713257
First received: October 22, 2012
Last updated: NA
Last verified: October 2012
History: No changes posted
  Purpose

This study intends to investigate the clinical outcomes of a new immunoenhancing formula which composed arginine free compare to isonitrogenous, isocaloric standard formula in ICU patients.The study design is multicenter, double-blind randomized controlled study with 3 periods of Screening, Run-in and Randomization period.

Primary Objective: To evaluate the clinical outcomes of immunoenhancing diet (IED) arginine free in medical-surgical ICU patients.

Secondary Objective: To evaluate the immunologic effects and safety of IED arginine free formula.


Condition Intervention Phase
Critical Illness
Dietary Supplement: Immunoenhancing diet
Dietary Supplement: Isocaloric, isonitrogenous diet
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Supportive Care
Official Title: A Comparative Randomized Controlled Study of Arginine Free Immunoenhancing Diet and Isocaloric, Isonitrogenous Formula in Critically Ill Patients

Resource links provided by NLM:


Further study details as provided by Thai Otsuka Pharmaceutical Co.,Ltd.:

Primary Outcome Measures:
  • Development of new organ failure [ Time Frame: 10 days ] [ Designated as safety issue: No ]
    Development of new organ failure: cardiovascular, respiratory, renal, hematologic, hepatic, neurologic Clinical outcomes: Change of SOFA score or MODS


Secondary Outcome Measures:
  • Immunologic parameters [ Time Frame: 10 days ] [ Designated as safety issue: Yes ]
    Immunologic: IL6, IL10, TNF-alpha Hospitalization day parameters: length of stay 28-day mortality Safety and tolerance; Nutritional parameters: caloric intake, body weight, nitrogen balance, serum albumin, electrolytes, minerals, serum chemistries GI complications: vomiting, diarrhea, constipation, abdominal distension, aspiration Infection complications (other than baseline): wound infection, pneumonia, urinary tract infection, intra-abdominal abscess and bacteremia


Enrollment: 172
Study Start Date: January 2011
Study Completion Date: October 2012
Primary Completion Date: October 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Immunoenhancing diet
Immunoenhancing diet feeding until Day 10 or the day of discharge if earlier than Day 10. The goal of caloric intake is 25 kcal/kg/day and protein 1.2 g/kg/day.
Dietary Supplement: Immunoenhancing diet
Enteral feeding until Day 10 or the day of discharge if earlier than Day 10. The goal of caloric intake is 25 kcal/kg/day and protein 1.2 g/kg/day.
Active Comparator: Isocaloric, isonitrogenous diet
Enteral feeding until Day 10 or the day of discharge if earlier than Day 10. The goal of caloric intake is 25 kcal/kg/day and protein 1.2 g/kg/day.
Dietary Supplement: Isocaloric, isonitrogenous diet
Enteral feeding until Day 10 or the day of discharge if earlier than Day 10. The goal of caloric intake is 25 kcal/kg/day and protein 1.2 g/kg/day.

Detailed Description:

It is accepted that nutrition support is essential in the treatment of critically ill patients. It is also reasonable to initiate nutrition support therapy as soon as possible. Although malnutrition is most frequently associated with a risk for immune dysfunction, it can affect all organ systems. Thus, ICU patients are in need of immunonutrients supplementation. An additional strategy to maximize the benefits is to consider using products supplemented with specific nutrients that modulate the immune system, improve wound healing, and reduce oxidative stress. The lower incidence of infectious complications may follow in shorter lengths of both intensive care units (ICU) and hospital stays. Many studies have concentrated on nutrients to stimulate the function of cellular immunity in these patients. These nutrients include arginine, glutamine and omega-3 fatty acid which has direct effect on T lymphocytes and macrophage. Enteral formulas designed as immune-enhancing diets (IED) contain supplemental amounts of L-arginine, L-glutamine, nucleotides and the long chain polyunsaturated fatty acids: eicosapentaenoic acid (EPA), docosahexanoic acid (DHA) and arachidonic acid (ARA) in addition to nutrient substrates essential for general nutrition and metabolism. These formulas vary considerably in composition of these four primary substrates. They introduce the immune cell function augmentation, inflammation regulation and infections minimization. Glutamine, a conditional-essential amino acid, an essential energy source, a precursor for protein synthesis and donates nitrogen for the synthesis of purines, pyrimidines, nucleotides, amino sugars, and glutathione antioxidant.

Glutamine also plays an important role in enhancing immune cell function with no elevation in proinflammatory cytokine production. The lower levels of glutamine have been associated with impaired tissue healing, immune dysfunction and increased mortality.

Omega-3 fatty acid (n-3 fatty acid or omega-3 fatty acid) directly affects the function of monocyte by membrane characteristic alteration, prostaglandin E2 (PGE2) synthesis that has the action of macrophage phagocytosis, IL-1 and superoxide synthesis. Moreover, omega-3 fatty acid reduces cellular immune response reaction by compete arachidonic acid resulting in less inflammation.

Arginine is considered a nutrient that enhances the immune response. Studies have shown arginine-supplemented immune formulas in helping decrease protein catabolism, improve nitrogen balance, enhance wound healing and wound strength resulted in less infection and shorter hospitalization days. Arginine has also been shown to support the immune system by enhancing lymphocyte proliferation and phagocytosis. Arginine may provide some benefits. However, recent meta-analysis conducted in a subgroup of critically ill patients by Heyland and colleagues revealed that arginine may be harmful to some group especially septic patients by stimulating nitric oxide (NO) production.

Based on these scientific rationales, it is recommended that arginine should not be used in critically ill patients who are clearly septic. And many evidences exist for supplementation with antioxidant and immunonutrition in the critically ill. Glutamine and fish oil/borage oil should be considered. These result in the development of immune-enhancing diet (IED) without arginine. In addition, two types of lipids are added into the formula to further modulate immune response. First, fish oil as a source of omega-3 fatty acids and borage oil as a source of docosahexanoic acid (DHA), a unique omega-6 fatty acid (n-6 fatty acid). Both n-3 and n-6 fatty acids are polyunsaturated fatty acids (PUFAs) and are essential fatty acids (EFA). Therefore, immune-enhancing diet composes of L-glutamine, eicosapentaenoic acid (EPA), docosahexanoic acid (DHA), antioxidant vitamins and trace minerals such as vitamin A, vitamin E, vitamin C, selenium and betacarotene.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. ICU patients requiring mechanical ventilation or APACHE II score equal or more than 10
  2. Patients arrived at ICU within 24 hours before feeding
  3. Anticipated tube feeding for at least 5 days
  4. Age of 18 years and older

Exclusion Criteria:

  1. Inability to be fed via the gastrointestinal tract
  2. Allergic to whey protein isolate (WPI), soy protein isolate, glutamine, fish oil or any components in study formulas
  3. Hemodynamically unstable, requiring significant dose of vasopressor or inotropes infusion (Dopamine or dobutamine > 5 microgram/kg/min or noradrenaline > 0.1 microgram/kg/min)
  4. Known insulin dependent diabetes mellitus
  5. Cerebral hemorrhage or severe head injury (Glasgow Coma Scale Score ≤ 8)
  6. Active bleeding requiring ongoing blood transfusion
  7. Platelet count < 30,000/mm3 or INR > 5
  8. Pre-existing incurable disease (uncontrolled cancer, terminal disease, patient's legal representative not committed to full support)
  9. On chemotherapy, radiation therapy within the previous 6 months or immunosuppressive regimen (including prednisolone or aspirin at least 7 days consecutively within the previous 4 weeks) or on other investigational drugs
  10. Any genetic immune or autoimmune disorder; known HIV-positive patients
  11. Severe chronic liver disease (Child- Pugh score of 11-15)
  12. Renal failure requiring renal replacement therapy
  13. Pregnancy or lactation
  14. Unable to obtain inform consent from patient or his/her legal representative
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01713257

Locations
Thailand
Assoc.Prof.Kaweesak Chittawatanarat
Muang, Chiang Mai, Thailand, 50200
Assoc.Prof.Boonsong Pachanasoonthorn
Muang, Khonkaen, Thailand
Songklanakarind Hospital
Haad Yai, Songkla, Thailand, 90110
Sponsors and Collaborators
Thai Otsuka Pharmaceutical Co.,Ltd.
Investigators
Principal Investigator: Assist.Prof.Boonsong Pajanasoontorn, MD Faculty of Medicine, Khon Kaen University
Principal Investigator: Kaweesak Chittawatanarat, M.D. Faculty of Medicine, Chiang Mai University
Principal Investigator: Burapat Sangthong, M.D. Department of Surgery, Faculty of Medicine, Songklanagarind University
Principal Investigator: Rungsun Bhurayanontachai, M.D. Department of Medicine, Faculty of Medicine, Songklanakarind University
  More Information

No publications provided

Responsible Party: Thai Otsuka Pharmaceutical Co.,Ltd.
ClinicalTrials.gov Identifier: NCT01713257     History of Changes
Other Study ID Numbers: CNN-TOP-2010-01
Study First Received: October 22, 2012
Last Updated: October 22, 2012
Health Authority: Thailand: Food and Drug Administration

Keywords provided by Thai Otsuka Pharmaceutical Co.,Ltd.:
Critically ill patients

Additional relevant MeSH terms:
Critical Illness
Disease Attributes
Pathologic Processes

ClinicalTrials.gov processed this record on July 22, 2014